The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ELCC 2017 | Maximizing treatment benefits in NSCLC
Nicolas Girard, MD, from the University Hospital of Lyon, Lyon, France discusses maximizing treatment benefits in non-small cell lung cancer (NSCLC), and the importance of defining different types of disease progression. The current recommendation for ALK-positive NSCLC patients is crizotinib, an ALK tyrosine kinase inhibitor (TKI), as a first-line treatment.
The field of NSCLC is rapidly evolving and new data will be presented at ASCO 2017. This interview was recorded at the annual meeting of European Lung Cancer Conference (ELCC) in Geneva, Switzerland.
